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ABSTRACT 
The aim of the study was to prepare and evaluate the Chlorzoxazone sustained release tablets by using natural gums in order to reduce the dose frequency and 
to improve the patient compliance. The tablets were prepared by direct compression method using natural gums such as Acacia (F1, F2 and F3), Guargum (F4, F5 
and F6) and Tragacanth (F7, F8 and F9) at different concentrations. The tablets were evaluated for weight variation, hardness, friability, thickness, drug content 
uniformity and in-vitro drug release. All the formulations have passed in physical characterization as per the standard limits in average weight, hardness, 
thickness, friability and drug content. FT-IR studies, reveals that the drug was compatible with excipients. Based on the in-vitro drug release F3, F6 and F9 
showed sustained release effect up to 12 hours (98.2%, 86.4% and 91.6%). Optimized formulation F6 was subjected to stability studies for two months at 28
oc 
and  45
oc  with 75±5% RH as per ICH guidelines and result does not shows any changes in physical parameters and in-vitro release studies. 
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INTRODUCTION 
Sustained drug delivery systems are aimed to control the rate 
of drug release and to maintain desire drug level in the blood 
which is therapeutically effective for an extended period of 
time.  Thus  the  reduction  of  both  total  dose  of  drug 
administered and the incidence of adverse side effects better 
patient compliance can be achieved
1, 2. The most commonly 
used method for modulating the drug release is to include it 
in  a  matrix  system
2.  Sustained  release  matrix  tablet  is 
relatively easy to fabricate by incorporating drug molecules 
in slowly disintegrating or inert porous materials. It is also 
called as controlled release delivery systems
3.  
Chlorzoxazone  (5-chloro-2,3-dihydro-1,3-benzoxazol-2-one) 
is  a  centrally  acting  muscle  relaxant  used  to  treat  muscle 
spasm and the resulting pain and discomfort 
4. Chlorzoxazone 
may act  by inhibiting calcium and potassium influx which 
would lead to neuronal inhibition and muscle relaxation. It is 
having  a  shorter  half  life  (1.1hour)  with  the  dose 
administration of 3-4 times a day leads to decreased patient 
compliance
  4,  5. In order to decrease the frequency of drug 
administration and for improving better patient compliance a 
sustained-release formulation of Chlorzoxazone is desirable.  
Natural gums are biodegradable and nontoxic, which hydrate 
and  swell  on  contact  with  aqueous  media,  and  these  have 
been  used  for  the  preparation  of  sustained  release  dosage 
form
6. Guar gum a polysaccharide derivative with glycoside 
linkage,  produced  from  the  guar  plant  seeds  (cyampopis 
tetragonolobus)  have  been  used  as  matrix  former  for 
controlled  release
7.  Gum  acacia  is  the  dried  gummy 
excaudate obtained from the stems and branches of acacia. It 
is  available  as  a  yellowish  or  white  colored  angular 
fragments
8.  Tragacanth  is  a  naturally  occurring  dried  gum 
obtained from Astragalus gummifer Labillardiere and other 
species  of  Astragalus.  The  gum  consists  of  a  mixture  of 
water-insoluble  and  water-soluble  poly-saccharides. 
Tragacanth gum is used as an emulsifying and suspending 
agent  in  a  variety  of  pharmaceutical  formulations
9.  Matrix 
tablets composed  of drug and polymer as release retarding 
material offer the simplest approach in designing a sustained 
release system
10.  
The aim of the present work was to prepare sustained release 
matrix tablets of Chlorzoxazone by using natural polymers 
such as Guar gum, Acacia, Tragacanth in varying proportions 
by direct compression method. 
MATERIALS AND METHODS 
Materials 
Chlorzoxazone was received as a gift sample from Panacea 
Biotech (Mohali). Guar gum, Acacia, Tragacanth, lactose and 
magnesium  stearate  were  purchased  from  Loba  Chemicals, 
Mumbai.  Talc  was  purchased  from  Micro  fine  chemicals, 
India. All other solvent and reagents were of analytical grade. 
Preparation of Chlorzoxazone SR tablets
9   
Sustained  release  tablets  each  containing  200mg 
Chlorzoxazone  were  prepared  by  direct  compression 
technique.  The  active  ingredient  and  polymers  at  various 
concentrations (45, 60, 75mg) were accurately weighed and 
passed  through  sieve  no.  45.  The  content  was  mixed 
thoroughly  in  a  mixer  for  10  minutes.  The  lubricant  and 
glidants were added to the above mixture and again mixed for 
5 minutes. Then the mixture was directly compressed on a 
Rotary Tablet Machine (Single punch, Inco) equipped with 
an  8  mm  standard  flat  faced  punch  and  die  set.  The 
compositions  of  different  tablet  formulations  are  shown  in 
Table-1. 
Drug-excipient Interaction studies 
11 
Preformulation studies are very important for the successful 
formulation of any dosage form. Fourier Transform Infrared 
(FTIR)  Spectroscopy  studies  were  performed  by  using 
Shimadzu FTIR spectrometer, which helps in the prediction 
of  interaction  of  the  drug  with  polymers,  diluents  and 
lubricants used in case tablet formulations. 
 PHYSICOCHEMICAL CHARACTERIZATION 
Thickness 
12 
Thickness of tablets was important for uniformity of tablet 
size.  The  thickness  of  the  tablet  was  measured  by  using 
digital vernier caliper, twenty tablets from each batch were 
randomly selected and thickness was measured. 
Weight variation 
12 
Twenty  tablets  were  randomly  selected  from  each  batch 
individually  weigh,  the  average  weight  and  standard 
deviation of 20 tablet calculated. Rajiya Begum.G et al. IRJP 2012, 3 (4) 
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Hardness
12 
Hardness was measured using Pfizer hardness tester, for each 
batch three tablet were tested. 
Friability
12 
Twenty  tablets  were  weighed  and  placed  in  the  Roche 
Friabilator and apparatus was rotated at 25 rpm for 4 min. 
After revolution the tablets were dusted weight. 
% loss=     X100 
Drug content uniformity 
12 
From  each  batch  of  prepared  tablets,  ten  tablets  were 
collected randomly and powdered. The powder equivalent to 
10  mg  of  Chlorzoxazone  was  transferred  in  to  10  ml  of 
volumetric flask to this 5 ml of methanol was added and then 
the solution was subjected to sonication for about 10 min. 
The solution was made up to the mark with methanol. The 
solution  was  filtered  and  suitable  dilutions  were  prepared 
with  ph  7.4  buffer.  Same  concentration  of  the  standard 
solution was also prepared. The drug content was estimated 
by  recording  the  absorbance  at  280.5  nm  by  using  UV-
Visible spectrophotometer. 
In vitro dissolution studies
13 
The dissolution studies were performed in triplicate for all the 
batches  in  a  USP  XXIII  dissolution  rate  test  apparatus 
(Campbell electronics, DR-6) employing the paddle stirrer.  
The release studies were performed at 75 rpm in 900 ml of 
phosphate  buffer  pH  7.4  at  37  ±  0.5ºC.  Five  milliliters 
aliquots  were  withdrawn  at  predefined  intervals,  and  the 
volume of the dissolution medium was maintained by adding 
the same volume of fresh pre warmed dissolution medium. 
The  absorbance  of  the  withdrawn  samples  was  measured 
spectro photometrically at 280.5 nm.   
Drug release kinetics
14, 15 
To analyze the mechanism of drug release rate kinetics, the 
results  of  In  vitro  release  profile  were  plotted  in  various 
kinetic  models  like  zero  order,  first  order,  Higuchi  and 
Krosmeyer-peppas  model  .The  methods  were  adopted  for 
deciding the most appropriate model. 
1. Cumulative percent drug released versus time (Zero order 
kinetic model) 
2. Log cumulative percent drug remaining versus time (First 
order kinetic model) 
3.  Cumulative  percent  drug released  versus  square  root  of 
time (Higuchi’s model). 
Zero order: 
In many of the modified release dosage forms, particularly 
sustained  or  controlled  release  dosage  forms  is  zero  order 
kinetic. The plot of cumulative percent drug released versus 
time is the linear.  
Q = Ko t 
Where, Q is the amount of drug release at time, t and Ko is 
the release rate constant. 
First order 
Most  conventional  dosage  forms  exhibits  this  dissolution 
mechanism. Some modified release preparation, particularly 
prolonged  release  formulations,  adheres  to  this  type  of 
dissolution  pattern.  It  assumes  that  the  drug  molecules, 
diffuses out through a gel like layer formed around the drug 
during  the  dissolution  process.  A  plot  of  log  cumulative 
percent drug remaining versus time is the linear. 
Log Q = K1t 
Where Q is the percent of drug release at time, t and K1 is the 
release rate constant 
 
 
Higuchi model 
A  large  number  of  modified  release  dosage  form  contain 
some  sort  of  matrix  system.  In  such  instances,  the  drug 
dissolves from the matrix. The dissolution pattern of the drug 
is dictated by water penetration rate (diffusion controlled). In 
Higuchi model, a plot of  cumulative percent drug released 
versus square root of time is linear. 
Q = K2t
1/2 
Where, Q is the percentage of drug release at time t and K2 is 
the diffusion rate constant 
Peppas Equation  
Q = Ktn 
Where, Q is the percent of drug release at time, t and K is the 
diffusion rate constant and n is diffusional exponent. If n is 
equal to one the release is zero order. If n is equal to 0.5 the 
release is best explained by fickian diffusion and if 0.5 < n < 
1 then the release is through anomalous diffusion or case II 
diffusion in this model a plot of % drug released versus log 
time is linear. 
Stability Studies  
Stability  testing  of  drug  products  begins as  a  part  of  drug 
discovery  and  ends  with  the  demise  of  the  compound  or 
commercial  product.  To  assess  the  drug  and  formulation 
stability,  stability  studies  were  done  according  to  ICH 
guidelines. The stability studies were carried out of the most 
satisfactory  formulation  as  per  ICH  guidelines.  The  most 
satisfactory  formulation sealed in aluminum packaging and 
kept in humidity chamber maintained at 30 ± 2 °C / 65 ± 5 % 
RH  for  two  months.  At  the  end  of  studies,  samples  were 
analyzed for the drug content, in vitro dissolution sustained 
behavior. 
RESULTS AND DISCUSSION 
Evaluation of Physical characterization 
Tablets  of  all  formulations  were  subjected  to  various 
physicochemical  evaluation  parameters  such  as  weight 
variation, thickness, diameter, hardness, friability, and drug 
content.  The results of these studies were also found to be 
within limits and were uniform given in Table-2. 
Compatibilty Studies 
The FTIR studies proved chemical and physical compatibility 
of drug with excipients which is shown in the Figure 1. 
In vitro Drug Dissolution Study 
The  results  of  dissolution  studies  showed  that  as  the 
concentration of polymer increases in the release of drug also 
retarding. The t50% of the formulation F1, F4 and F7 is with in 
4 hours where as for the formulation F2, F5 and F8 showed 
nearly six hours. The polymers in high concentration showed 
t50%  more  than  six  hours.  The  formulations  with  high 
concentration F3, F6, F9 shows the sustained release of the 
drug  up  to  12  hrs  which  are  found  to  be  F3  (98.2%),  F6 
(86.4%),  F9  (96.6%).  Among  the  nine  formulations  F6 
formulation showed good sustained activity. In vitro release 
study results revealed that the release of drug was retarded 
with the proportional increase of the polymer concentration. 
It was observed that the amount of polymer influences the 
drug release which is shown in Figure 2-5. 
Drug Release Kinetics 
The release data was fitted to various mathematical models to 
evaluate the kinetics and the mechanism of drug release. The 
data was analyzed for the optimized formulations F3, F6 and 
F9  and  the  r
2  values  are  tabulated  in  Table-3.  Among  the 
models, zero order, Higuchi, Hixson-crowell and Krosmeyer 
peppas the above three formulation F3, F6 and F9 were best 
fitted in Krosmeyer-peppas and its r
2 values were found to be Rajiya Begum.G et al. IRJP 2012, 3 (4) 
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0.9926  (F3),  0.9954  (F6)  and  0.9856  (F9)  which  indicates 
diffusion is the mechanism of drug release. 
Stability Studies 
The  optimized  formulation  (F6)  was  further  evaluated  for 
stability studies as per ICH guidelines mention earlier. It was 
suggested that there was no significant changes in physical 
parameters like hardness, thickness, weight variation, content 
uniformity.  In-vitro release  profile  of  optimized  batch  (F6) 
was shown in Figure 6. Thus formulation was stable at given 
condition of temperature and humidity for 2 month period of 
time. 
CONCLUSION 
From  the  above  study  it  may  be  concluded  that  at  higher 
concentration of Guargum and Tragacanth were retarded the 
release of Chlorzoxazone. As the concentration of polymer 
increases the release of drug was retarded.  Thus the polymer 
concentrations  were  optimized  for  producing  the  oral  SR 
tablets  of  Chlorzoxazone.  The  mechanism  of  drug  release 
observed to be following may be Korsmeyer-Peppas model 
which depicts diffusion is the mechanism of drug release. 
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TABLE NO 1: FORMULATION OF CHLORZAXONE TABLETS 
Ingredients  Weight in (mg) 
F1  F2  F3  F4  F5  F6  F7  F8  F9 
Chlorzoxazone  10  10  10  10  10  10  10  10  10 
Acacia  45  60  75  ---  ---  ---  ---  ---  --- 
Guargum  ---  ---  ---  45  60  75  ---  ---  --- 
Tragacanth  ---  ---  ---  ---  ---  ---  45  60  75 
Lactose  141  126  111  141  126  111  141  126  111 
Talc  2  2  2  2  2  2  2  2  2 
Magnesium Stearate  2  2  2  2  2  2  2  2  2 
Total  200  200  200  200  200  200  200  200  200 
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TABLE NO 2: PHYSICAL CHARACTERSTICS OF CHLORZOXAZONE TABLETS 
Formulations  Weight variation(mg) 
Fraibility 
(%) 
Hardness 
(kg/cm
2 ) 
Thickness 
(mm) 
Diameter 
(mm)  Drug  content (%) 
F1  197.560±1.078  0.58±0.028  5.2±0.141  2.5±0.141  8±0.01  96.15±0.212 
F2  197.000±1.412  0.48±0.038  5.65±0.070  2.20±0.141  8±0.01  101.10±1.202 
F3  196.990±1.127  0.49±0.028  5.65±0.212  2.35±0.141  8±001.  95.60±0.282 
F4  197.730±1.441  0.33±0.049  5.10±0.282  2.15±0.141  8±0.03  96.75±0.353 
F5  196.960±1.286  0.72±0.035  5.10±0.282  2.45±0.141  8±0.01  97.75±0.494 
F6  196.945±1.265  0.29±0.021  5.15±0.353  2.20±0.141  8±0.02  98.10±0.282 
F7  197.180±1.401  0.32±0.035  5.15±.212  2.20±0.141  8±0.01  98.25±0.212 
F8  196.930±1.313  0.55±0.014  5.70±0.141  2.30±0.141  8±0.02  99.65±0.070 
F9  197.500±1.231  0.34±0.007  5.60±0.282  2.25±0.141  8±0.01  98.60±0.424 
*above values shows Mean ± S.D 
 
TABLE NO 3: KINETIC RELEASE DATA FOR THE OPTIMIZED FORMULATIONS 
 
MODEL 
R
2
  VALUE 
F3  F6  F9 
Zero order  0.9631  0.9961  0.9769 
First order  0.8543  0.8519  ---- 
Higuchi  0.9421  0.9742  0.9553 
Krosmeyer peppas  0.9926  0.9954  0.9856 
 
TABLE NO 4: STABILITY STUDIES: DRUG CONTENT 
Formulation  Initial Amount  30 ± 2 °C / 65 ± 5 % RH after 
1month 
30 ± 2 °C / 65 ± 5 % RH after 2
nd 
month 
F6  98.10±0.282  97.50±0.212  97.46±0.201 
 
 
 
Figure 1: FTIR Spectrum of Chlorzoxazone (A), FTIR Spectrum of Acacia (B), FTIR Spectrum of GuarGum (C), FTIR Spectrum of Tragacanth (D). 
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Figure 2: Comparative in vitro drug release profile of formulations F1-F3 
 
 
Figure 3: Comparative in vitro drug release profile of formulations F4-F6 
 
 
Figure 4: Comparative in vitro drug release profile of formulations F7-F9 
 
 
Figure 5: Comparative percentage cumulative release of Chlorzoxazone formulation indicates the maximum time taken for the drug release 
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Figure 6: Comparative Stability dissolution studies of formulations F6 
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